Simcere Pharmaceutical Group Limited

SEHK:2096 Stock Report

Market Cap: HK$31.0b

Simcere Pharmaceutical Group Future Growth

Future criteria checks 3/6

Simcere Pharmaceutical Group is forecast to grow earnings and revenue by 17.4% and 17.4% per annum respectively. EPS is expected to grow by 16.6% per annum. Return on equity is forecast to be 18.2% in 3 years.

Key information

17.4%

Earnings growth rate

16.63%

EPS growth rate

Pharmaceuticals earnings growth13.1%
Revenue growth rate17.4%
Future return on equity18.17%
Analyst coverage

Low

Last updated21 Aug 2026

Recent future growth updates

Analysis Article • Mar 29

Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for Simcere Pharmaceutical Group Limited ( HKG:2096 ) shareholders, because the company has just...

Recent updates

Analysis Article • Jun 21

Simcere Pharmaceutical Group (SEHK:2096) Stock Could Be 70% Below Fair Value After Stanford IPF Deal

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after agreeing to fund an exploratory idiopathic pulmonary fibrosis project with Stanford Medicine, securing an option to in-license a first in class molecule with full global rights. See our latest analysis for Simcere Pharmaceutical Group. The Stanford IPF collaboration comes at a time when Simcere Pharmaceutical Group’s shares are trading at HK$9.58, with a 30 day share price return down 9.62% and a year to date share price...
Analysis Article • May 07

Simcere Pharmaceutical Group's (HKG:2096) Solid Profits Have Weak Fundamentals

Simcere Pharmaceutical Group Limited ( HKG:2096 ) announced strong profits, but the stock was stagnant. We did some...
Analysis Article • Mar 29

Simcere Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for Simcere Pharmaceutical Group Limited ( HKG:2096 ) shareholders, because the company has just...
Analysis Article • Jan 16

Simcere Pharmaceutical Group Limited (HKG:2096) Shares Could Be 48% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Simcere Pharmaceutical Group is HK$22.34 based on 2 Stage Free Cash Flow to...
Analysis Article • Jul 29

Simcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors

Despite an already strong run, Simcere Pharmaceutical Group Limited ( HKG:2096 ) shares have been powering on, with a...
Analysis Article • May 20

Simcere Pharmaceutical Group Limited (HKG:2096) Looks Just Right With A 28% Price Jump

Simcere Pharmaceutical Group Limited ( HKG:2096 ) shareholders have had their patience rewarded with a 28% share price...
Analysis Article • May 06

We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit

Simcere Pharmaceutical Group Limited ( HKG:2096 ) announced a healthy earnings result recently, and the market rewarded...
Analysis Article • Mar 06

Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues

When close to half the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios (or "P/S...
Analysis Article • Nov 21

Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Simcere Pharmaceutical Group Limited's ( HKG:2096 ) price-to-sales (or "P/S") ratio of 2.5x may not look like an...
Analysis Article • Jul 29

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Simcere Pharmaceutical Group Limited's ( HKG:2096 ) price-to-earnings (or "P/E") ratio of 17.5x might make it look like...
Analysis Article • May 01

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Simcere Pharmaceutical Group Limited's ( HKG:2096 ) recent weak earnings report didn't cause a big stock movement. Our...
Analysis Article • Dec 29

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may consider...
Analysis Article • Aug 28

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

The analysts covering Simcere Pharmaceutical Group Limited ( HKG:2096 ) delivered a dose of negativity to shareholders...

Earnings and Revenue Growth Forecasts

SEHK:2096 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202813,7872,411N/AN/A4
12/31/202711,3912,022N/AN/A5
12/31/202610,0881,705N/AN/A5
6/30/20268,7271,572N/AN/AN/A
3/31/20268,2291,458N/AN/AN/A
12/31/20257,7311,3441,1512,014N/A
9/30/20257,4191,1079211,704N/A
6/30/20257,1078807051,395N/A
3/31/20256,8718076671,393N/A
12/31/20246,6357226161,391N/A
9/30/20246,487-1904281,243N/A
6/30/20246,340-1,1022401,096N/A
3/31/20246,474-194-294623N/A
12/31/20236,608715-829151N/A
9/30/20236,8071,928-504369N/A
6/30/20237,0063,141-179587N/A
3/31/20236,6652,036249971N/A
12/31/20226,3249316761,354N/A
9/30/20225,9529726731,180N/A
6/30/20225,5791,0136711,006N/A
3/31/20225,2901,260130402N/A
12/31/20215,0001,507-411-202N/A
9/30/20214,8521,274-481-200N/A
6/30/20214,7031,042-551-198N/A
3/31/20214,606856-404-51N/A
12/31/20204,509670-25697N/A
9/30/20204,528699-314-6N/A
6/30/20204,548728-371-109N/A
3/31/20204,792866N/A332N/A
12/31/20195,0371,004N/A773N/A
12/31/20184,514734N/A776N/A
12/31/20173,868350N/A939N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2096's forecast earnings growth (17.4% per year) is above the savings rate (3.1%).

Earnings vs Market: 2096's earnings (17.4% per year) are forecast to grow faster than the Hong Kong market (11.7% per year).

High Growth Earnings: 2096's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2096's revenue (17.4% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).

High Growth Revenue: 2096's revenue (17.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2096's Return on Equity is forecast to be low in 3 years time (18.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/22 03:06
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Simcere Pharmaceutical Group Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shaojing TongBofA Global Research
Bo YuChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.